Search
Quanterix sees a bright future for blood biomarkers
A new dawn breaks for blood tests in neurological diseases, though future data remain important.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Asco 2023 preview – a microcap winner
One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.
Pfizer posts another haemophilia hit
The group is taking marstacimab to the regulators, but Novo’s MAb looks like a bad omen.
Asco 2023 preview – Tigit lives again
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Asco 2023 – Regeneron nips at Bristol’s heels in Lag3
Fianlimab continues to look like biopharma’s leading Lag3 asset, with activity in a new melanoma setting to boot.
Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
Heightened US antitrust fears rattle biopharma
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
2023’s biggest launches: the story so far
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
Iteos – and GSK – keep the faith
With Tigit out of favour Belgium’s Iteos reckons it could have the best possible PD-(L)1 combo, but does GSK share its optimism?
Astellas doesn’t buy Apellis
In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.
Sanofi pumps up its Pompe portfolio with Maze deal
In licensing Maze’s oral contender, the group has made another bet against gene therapies.
Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Tecentriq runs out of luck in triple-negative breast cancer
Roche puts on a brave face as its anti-PD-L1 drug fails yet another TNBC study, this time in the adjuvant setting.